| 9.5 0 (0%) | 01-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.27 | 1-year : | 13.16 |
| Resists | First : | 9.64 | Second : | 11.27 |
| Pivot price | 9.48 |
|||
| Supports | First : | 9.42 | Second : | 9.27 |
| MAs | MA(5) : | 9.49 |
MA(20) : | 9.48  |
| MA(100) : | 4.73 |
MA(250) : | 3.73 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 52.8 |
| RSI | RSI(14): 75.3 | |||
| 52-week | High : | 9.64 | Low : | 1.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PSTX ] has closed below upper band by 42.4%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.51 - 9.55 | 9.55 - 9.59 |
| Low: | 9.38 - 9.43 | 9.43 - 9.48 |
| Close: | 9.41 - 9.5 | 9.5 - 9.57 |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Wed, 08 Jan 2025
Roche Completes Major Acquisition of Poseida Therapeutics with 66% Share Tender Success - StockTitan
Tue, 07 Jan 2025
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 12-Month High - What's Next? - MarketBeat
Fri, 20 Dec 2024
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Fri, 13 Dec 2024
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Thu, 28 Nov 2024
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - Yahoo Finance
Wed, 27 Nov 2024
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 27.6 (%) |
| Held by Institutions | 58.4 (%) |
| Shares Short | 3,590 (K) |
| Shares Short P.Month | 4,610 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.88 |
| Profit Margin | -40.3 % |
| Operating Margin | 27.5 % |
| Return on Assets (ttm) | -13.2 % |
| Return on Equity (ttm) | -57.7 % |
| Qtrly Rev. Growth | 667.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.54 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -15.08 |
| PEG Ratio | 0 |
| Price to Book value | 10.67 |
| Price to Sales | 6.13 |
| Price to Cash Flow | -61.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|